Effects of Bisphosphonate Treatment on Circulating Lipid and Glucose Levels in Patients with Metabolic Bone Disorders.
Bisphosphonate
Cholesterol
Glucose
Osteoporosis
Paget’s disease of bone
Triglycerides
Journal
Calcified tissue international
ISSN: 1432-0827
Titre abrégé: Calcif Tissue Int
Pays: United States
ID NLM: 7905481
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
22
08
2020
accepted:
15
01
2021
pubmed:
10
2
2021
medline:
19
8
2021
entrez:
9
2
2021
Statut:
ppublish
Résumé
Bisphosphonates are the first-choice treatment of osteoporosis and Paget's disease of bone. Among the bisphosphonates, the non-amino-bisphosphonates, such as clodronic acid, are intracellular converted into toxic analogues of ATP and induce cellular apoptosis whereas the amino-bisphosphonates, such as zoledronic acid, inhibit the farnesyl-diphosphate-synthase, an enzyme of the mevalonate pathway. This pathway regulates cholesterol and glucose homeostasis and is a target for statins. In this retrospective cohort study, we evaluated the effects of an intravenous infusion of zoledronic acid (5 mg) or clodronic acid (1500 mg) on blood lipid (i.e. total cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol and triglycerides) and glucose levels in patients with osteoporosis and Paget's disease of bone. All patients were evaluated before, 1 and 6 months after bisphosphonate treatment. Pagetic and osteoporotic patients treated with zoledronic acid showed a significant reduction in glucose and atherogenic lipids during follow-up whereas these phenomena were not observed after clodronic treatment. The effect on circulating lipid levels was similar in naïve and re-treated Pagetic patients. Zoledronic acid treatment was associated with a reduction in blood glucose and atherogenic lipids in patients with metabolic bone disorders. The extent of change was similar to that obtained with the regular assumption of a low-intensity statin. Further studies are warranted to better evaluate the clinical implications of these observations.
Identifiants
pubmed: 33559705
doi: 10.1007/s00223-021-00811-w
pii: 10.1007/s00223-021-00811-w
pmc: PMC8166716
doi:
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Lipids
0
Zoledronic Acid
6XC1PAD3KF
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
757-763Références
Lorenzatti AJ, Toth PP (2020) New perspectives on atherogenic dyslipidaemia and cardiovascular disease. Eur Cardiol 15:1–9
pubmed: 32180834
Veronese N, Stubbs B, Crepaldi G, Solmi M, Cooper C, Harvey NC, Reginster JY, Rizzoli R, Civitelli R, Schofield P, Maggi S, Lamb SE (2017) Relationship between low bone mineral density and fractures with incident cardiovascular disease: a systematic review and meta-analysis. J Bone Miner Res 32:1126–1135
pubmed: 28138982
pmcid: 5417361
Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW (2009) Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 94:1853–1878
pubmed: 19494161
pmcid: 5393375
Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733
pubmed: 16983459
Seitz S, Priemel M, von Domarus C, Beil FT, Barvencik F, Amling M, Rueger JM (2008) The second most common bone disease: a review on Paget’s disease of bone. Eur J Trauma Emerg Surg 34:549–553
pubmed: 26816278
Corral-Gudino L, Borao-Cengotita-Bengoa M, Del Pino-Montes J, Ralston S (2013) Epidemiology of Paget’s disease of bone: a systematic review and meta-analysis of secular changes. Bone 55:347–352
pubmed: 23643679
van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C (2002) Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res 17:465–471
pubmed: 11878305
Rendina D, Gennari L, De Filippo G, Merlotti D, de Campora E, Fazioli F, Scarano G, Nuti R, Strazzullo P, Mossetti G (2006) Evidence for increased clinical severity of familial and sporadic Paget’s disease of bone in Campania, southern Italy. J Bone Miner Res 21:1828–1835
pubmed: 17002563
Gennari L, Rendina D, Falchetti A, Merlotti D (2019) Paget’s disease of bone. Calcif Tissue Int 104:483–500
pubmed: 30671590
Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9:2643–2658
pubmed: 14529538
Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ (1999) Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 56:131–140
pubmed: 10385693
Buhaescu I, Izzedine H (2007) Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 40:575–584
pubmed: 17467679
Rendina D, De Filippo G, Merlotti D, Di Stefano M, Succoio M, Muggianu SM, Bianciardi S, D’Elia L, Coppo E, Faraonio R, Nuti R, Strazzullo P, Gennari L (2019) Vitamin D status in Paget disease of bone and efficacy-safety profile of cholecalciferol treatment in Pagetic patients with hypovitaminosis D. Calcif Tissue Int 105:412–422
pubmed: 31236621
Rendina D, Gianfrancesco F, De Filippo G, Merlotti D, Esposito T, Mingione A, Nuti R, Strazzullo P, Mossetti G, Gennari L (2010) FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women. Eur J Endocrinol 163:165–172
pubmed: 20335500
Rossini M, Adami S, Bertoldo F, Diacinti D, Gatti D, Giannini S, Giusti A, Malavolta N, Minisola S, Osella G, Pedrazzoni M, Sinigaglia L, Viapiana O, Isaia GC (2016) Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo 68:1–39
pubmed: 27339372
Gennari L, Merlotti D, Mossetti G, Rendina D, De Paola V, Martini G, Nuti R (2009) The use of intravenous aminobisphosphonates for the treatment of Paget’s disease of bone. Mini Rev Med Chem 9:1052–1063
pubmed: 19689402
Mossetti G, Gennari L, Rendina D, De Filippo G, Merlotti D, De Paola V, Fusco P, Esposito T, Gianfrancesco F, Martini G, Nuti R, Strazzullo P (2008) Vitamin D receptor gene polymorphisms predict acquired resistance to clodronate treatment in patients with Paget’s disease of bone. Calcif Tissue Int 83:414–424
pubmed: 19020788
Merlotti D, Rendina D, Muscariello R, Picchioni T, Alessandri M, De Filippo G, Materozzi M, Bianciardi S, Franci MB, Lucani B, Cenci S, Strazzullo P, Nuti R, Gennari L (2020) Preventive role of vitamin D supplementation for acute phase reaction after bisphosphonate infusion in Paget’s disease. J Clin Endocrinol Metab 105:dgz138
pubmed: 31634910
Tufano A, Rendina D, Conca P, Matani B, Di Minno G (2019) Hypocalcemia and hypophosphatemia after treatment with zoledronic acid in a patient with AL amyloidosis. Intern Emerg Med 14:447–449
pubmed: 30771083
Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115:1531–1543
pubmed: 19197972
pmcid: 2813207
Rendina D, De Filippo G, Ralston SH, Merlotti D, Gianfrancesco F, Esposito T, Muscariello R, Nuti R, Strazzullo P, Gennari L (2015) Clinical characteristics and evolution of giant cell tumor occurring in Paget’s disease of bone. J Bone Miner Res 30:257–263
pubmed: 25196811
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612
pubmed: 19414839
pmcid: 19414839
Cooper DS, Biondi B (2012) Subclinical thyroid disease. Lancet 379:1142–1154
pubmed: 22273398
Fillée C, Keller T, Mourad M, Brinkmann T, Ketelslegers JM (2012) Impact of vitamin D-related serum PTH reference values on the diagnosis of mild primary hyperparathyroidism, using bivariate calcium/PTH reference regions. Clin Endocrinol (Oxf) 76:785–789
Adhyaru BB, Jacobson TA (2018) Safety and efficacy of statin therapy. Nat Rev Cardiol 15:757–769
Gozzetti A, Gennari L, Merlotti D, Salvadori S, De Paola V, Avanzati A, Franci B, Marchini E, Tozzi M, Campagna MS, Nuti R, Lauria F, Martini G (2008) The effects of zoledronic acid on serum lipids in multiple myeloma patients. Calcif Tissue Int 82:258–262
pubmed: 18418538
GBD 2013 Mortality and Causes of Death Collaborators (2015) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study. Lancet 2015(385):117–171
Lello S, Capozzi A, Scambia G (2015) Osteoporosis and cardiovascular disease: an update. Gynecol Endocrinol 31:590–594
pubmed: 26036806
Rendina D, De Filippo G, Muscariello R, De Palma D, Fiengo A, De Pascale F, Strazzullo P (2014) Vitamin D and cardiometabolic disorders. High Blood Press Cardiovasc Prev 21:251–256
pubmed: 25200767
Lampropoulos CE, Papaioannou I, D’Cruz DP (2012) Osteoporosis-a risk factor for cardiovascular disease? Nat Rev Rheumatol 8:587–598
pubmed: 22890244
Sato M, Asada N, Kawano Y, Wakahashi K, Minagawa K, Kawano H, Sada A, Ikeda K, Matsui T, Katayama Y (2013) Osteocytes regulate primary lymphoid organs and fat metabolism. Cell Metab 18:749–758
pubmed: 24140021
Bone HG (2006) Nonmalignant complications of Paget’s disease. J Bone Miner Res 21:P64–P68
pubmed: 17229011
Gianfrancesco F, Rendina D, Merlotti D, Esposito T, Amyere M, Formicola D, Muscariello R, De Filippo G, Strazzullo P, Nuti R, Vikkula M, Gennari L (2013) Giant cell tumor occurring in familial Paget’s disease of bone: report of clinical characteristics and linkage analysis of a large Pedigree. J Bone Miner Res 28:341–350
pubmed: 22936311
Morales-Piga AA, Moya JL, Bachiller FJ, Muñoz-Malo MT, Benavides J, Abraira V (2000) Assessment of cardiac function by echocardiography in Paget’s disease of bone. Clin Exp Rheumatol 18:31–37
pubmed: 10728441
Arnalich F, Plaza I, Sobrino JA, Oliver J, Barbado J, Peña JM, Vazquez JJ (1984) Cardiac size and function in Paget’s disease of bone. Int J Cardiol 5:491–505
pubmed: 6233229
Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M (2005) Bisphosphonates and atherosclerosis: why? Lupus 14:773–779
pubmed: 16218486
Persy V, De Broe M, Ketteler M (2006) Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels? Kidney Int 70:1537–1538
pubmed: 17051257
Guney E, Kisakol G, Ozgen AG, Yilmaz C, Kabalak T (2008) Effects of bisphosphonates on lipid metabolism. Neuro Endocrinol Lett 29:252–255
pubmed: 18404138
Gonnelli S, Caffarelli C, Tanzilli L, Pondrelli C, Lucani B, Franci BM, Nuti R (2014) Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women. Bone 61:27–32
pubmed: 24389416
Passeri E, Mazzaccaro D, Sansoni V, Perego S, Nano G, Verdelli C, Lombardi G, Corbetta S (2019) Effects of 12-months treatment with zoledronate or teriparatide on intima-media thickness of carotid artery in women with postmenopausal osteoporosis: a pilot study. Int J Immunopathol Pharmacol 33:2058738418822439
pubmed: 30791743
pmcid: 6327329
Sing CW, Wong AY, Kiel DP, Cheung EY, Lam JK, Cheung TT, Chan EW, Kung AW, Wong IC, Cheung CL (2018) Association of alendronate and risk of cardiovascular events in patients with hip fracture. J Bone Miner Res 33:1422–1434
pubmed: 29744914
Vestergaard P (2012) Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones? Calcif Tissue Int 90:22–29
pubmed: 22120197
Lu P-Y, Hsieh C-F, Tsai Y-W, Huang W-F (2011) Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. Clin Ther 33:1173–1179
pubmed: 21849210
Kang JH, Keller JJ, Lin HC (2012) A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke. Osteoporos Int 23:2551–2557
pubmed: 22270858
Rendina D, De Filippo G, Strazzullo P (2010) Should vitamin D status be assessed in patients with congestive heart failure? Nutr Metab Cardiovasc Dis 20:627–632
pubmed: 20947319
Greco EA, Lenzi A, Migliaccio S (2019) Role of hypovitaminosis D in the pathogenesis of obesity-induced insulin resistance. Nutrients 11:E1506
pubmed: 31266190
Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure–activity relationships for inhibition of farnesyldiphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235–242
pubmed: 11160603